HC Wainwright Has Negative Estimate for EVAX FY2025 Earnings

Evaxion Biotech A/S (NASDAQ:EVAX) – Equities research analysts at HC Wainwright lowered their FY2025 earnings per share estimates for Evaxion Biotech A/S in a report released on Wednesday, April 2nd. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.03) for the year, down from their prior estimate of ($0.01). HC Wainwright currently has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.15) per share. HC Wainwright also issued estimates for Evaxion Biotech A/S’s FY2026 earnings at ($0.02) EPS.

Separately, Lake Street Capital reduced their target price on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th.

Evaxion Biotech A/S Stock Performance

Shares of NASDAQ:EVAX opened at $1.51 on Monday. Evaxion Biotech A/S has a 1 year low of $1.50 and a 1 year high of $22.05. The stock has a market capitalization of $1.77 million, a price-to-earnings ratio of -1.04 and a beta of -0.25. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. The company’s 50 day simple moving average is $2.30 and its 200 day simple moving average is $6.68.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its earnings results on Tuesday, April 1st. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.19. The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $1.66 million.

Institutional Investors Weigh In On Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC bought a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned approximately 2.98% of Evaxion Biotech A/S at the end of the most recent reporting period. Institutional investors and hedge funds own 11.04% of the company’s stock.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.